Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 7;6(3):111-115.
doi: 10.14744/hf.2025.2025.0050. eCollection 2025.

Non-invasive tests for resmetirom treatment fail to accurately define the target population: Evidence from a biopsy-proven MASLD cohort

Eda Kaya  1   2 , Sinem Aksoy  3 , Nazlican Oruc  3 , Cagla Tasdemir  3 , Beyza Irem Cengiz  3 , Caglayan Keklikkiran  2   4 , Yusuf Yilmaz  2   4
Affiliations

Non-invasive tests for resmetirom treatment fail to accurately define the target population: Evidence from a biopsy-proven MASLD cohort

Eda Kaya et al. Hepatol Forum. .

Abstract

Background and aim: Resmetirom received conditional Food and Drug Administration (FDA) approval in 2024 for metabolic dysfunction-associated steatotic liver disease (MASLD) based on its promising liver-targeted therapy. Clinical trials required a histological diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) with F2-F3 fibrosis, excluding cirrhosis, while real-world prescribing relies on non-invasive tests (NITs). This study evaluates their efficacy in identifying the target population within a biopsy-proven Turkish MASLD cohort.

Materials and methods: We analyzed 266 patients with biopsy-proven MASLD from the Turkish NAFLD Biobank. Inclusion required AST >17 U/L (females) or >20 U/L (males), and CAP ≥280 dB/m. Eligibility was defined by liver stiffness measurement (LSM) of 10-19.9 kPa (excluding cirrhosis or low platelet count) or a FAST score ≥0.67.

Results: Among the study population, 130 patients (48.9%) had histologically confirmed MASH with F2-F3 fibrosis. Based on LSM criteria applied to histologically eligible patients, 81 patients (62.3%) were underdiagnosed, compared to 95 patients (73.1%) when using the FAST score. Additionally, among patients who corresponded to NIT, 34 patients (41.0%) were overprescribed using LSM, while 23 patients (39.7%) were overprescribed using the FAST score. The kappa value as a measure of agreement showed poor compatibility for both LSM and FAST with liver biopsy (0.128 and 0.101, respectively). When treatment decisions were guided by either of the NITs, 44 patients (44.0%) received unnecessary prescriptions, and 74 patients (44.6%) had missed diagnoses.

Conclusion: The NITs defined for identifying the target population for resmetirom demonstrated poor performance in accurately detecting or excluding eligible patients. Therefore, performing a liver biopsy before starting resmetirom treatment will prevent unnecessary increases in cost and significantly reduce the economic burden of the treatment.

Keywords: Fibrosis; MASLD; MASH; non-invasive test; resmetirom.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

Figure 1
Figure 1
Comparison of diagnostic performances of algorithms including LSM and FAST.
See this image and copyright information in PMC

References

    1. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–1347. doi: 10.1097/HEP.0000000000000004. - DOI - PMC - PubMed
    1. Degertekin B, Tozun N, Demir F, Soylemez G, Parkan S, Gurtay E, et al. The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade. Turk J Gastroenterol. 2021;32(3):302–312. doi: 10.5152/tjg.2021.20062. - DOI - PMC - PubMed
    1. Yilmaz Y, Yilmaz N, Ates F, Karakaya F, Gokcan H, Kaya E, et al. The prevalence of Metabolic Associated Fatty Liver Disease in The Turkish population: A multicenter study. Hepatol Forum. 2021;2(2):37–42. doi: 10.14744/hf.2021.2020.0033. - DOI - PMC - PubMed
    1. Le P, Tatar M, Dasarathy S, Alkhouri N, Herman WH, Taksler GB, et al. Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050. JAMA Netw Open. 2025;8:e2454707. doi: 10.1001/jamanetworkopen.2024.54707. - DOI - PMC - PubMed
    1. Younossi ZM, Stepanova M, Al Shabeeb R, Eberly KE, Shah D, Nguyen V, et al. The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease. Hepatology Communications. 2024;8(1):e0352. doi: 10.1097/HC9.0000000000000352. - DOI - PMC - PubMed

LinkOut - more resources